| Recruiting | Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease NCT07478172 | University of Missouri-Columbia | N/A |
| Not Yet Recruiting | A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases NCT07304154 | Kite, A Gilead Company | Phase 1 |
| Not Yet Recruiting | Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients Wit NCT07392528 | Tianjin Huanhu Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Tongji NADs Cohort NCT07333196 | Tongji Hospital | — |
| Recruiting | A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gr NCT07250750 | ImmunAbs Inc. | Phase 1 / Phase 2 |
| Recruiting | Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis NCT07217587 | Janssen Research & Development, LLC | Phase 3 |
| Not Yet Recruiting | Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis NCT07224386 | BioSensics | — |
| Recruiting | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Particip NCT07284420 | argenx | Phase 2 |
| Recruiting | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens i NCT07294170 | argenx | — |
| Not Yet Recruiting | Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?" NCT06866652 | Institut de Myologie, France | — |
| Recruiting | Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized NCT07246564 | UCB Biopharma SRL | Phase 4 |
| Recruiting | Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis NCT07411963 | Centre Hospitalier Universitaire de Nice | — |
| Not Yet Recruiting | Integrating Art Therapy and Adapted Physical Activity: Toward Improved Quality of Life in Patients With Myasth NCT07125105 | Universite du Littoral Cote d'Opale | N/A |
| Enrolling By Invitation | PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry NCT07217509 | CorEvitas | — |
| Withdrawn | Oxaloacetate in Myasthenia Gravis NCT04965987 | University of Kansas Medical Center | Phase 1 |
| Not Yet Recruiting | Efgartigimod for Consolidation Therapy in gMG NCT07079020 | Da, Yuwei, M.D. | — |
| Recruiting | Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD1 NCT06939166 | Tianjin Huanhu Hospital | EARLY_Phase 1 |
| Recruiting | A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases NCT06869278 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Not Yet Recruiting | UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases NCT06978738 | Changzhou No.2 People's Hospital | Phase 1 |
| Recruiting | A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-relat NCT06626919 | Arcellx, Inc. | Phase 1 |
| Recruiting | Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases NCT07022197 | Tianjin Medical University General Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis NCT06933563 | Zhejiang University | EARLY_Phase 1 |
| Not Yet Recruiting | Blinatumomab for Treatment of Refractory Myasthenia Gravis NCT06836973 | Da, Yuwei, M.D. | Phase 2 / Phase 3 |
| Recruiting | Capturing Key MG-symptoms Using Smartphone Recordings. NCT06743490 | Leiden University Medical Center | — |
| Recruiting | Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months NCT06815133 | Centre Hospitalier Universitaire de Nice | — |
| Recruiting | Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired Wit NCT06866483 | ZS Associates | — |
| Not Yet Recruiting | Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis NCT06827587 | First Affiliated Hospital of Wenzhou Medical University | N/A |
| Enrolling By Invitation | Prevalence and Impact of Fatigue in Myasthenic Patients Followed At Clermont-Ferrand University Hospital - "My NCT06877403 | University Hospital, Clermont-Ferrand | — |
| Recruiting | A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Gen NCT06688435 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Recruiting | Interventions Against Fatigue in Patients With Myasthenia Gravis NCT06659627 | Leiden University Medical Center | N/A |
| Not Yet Recruiting | Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis NCT06723548 | First Affiliated Hospital of Wenzhou Medical University | Phase 4 |
| Recruiting | A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa NCT06298565 | argenx | — |
| Active Not Recruiting | A Study in Patients With Myasthenia Gravis in China NCT06700616 | AstraZeneca | — |
| Recruiting | Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis NCT06491238 | HealthPartners Institute | N/A |
| Enrolling By Invitation | Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disor NCT06605612 | LMU Klinikum | — |
| Recruiting | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia NCT06193889 | Kyverna Therapeutics | Phase 2 / Phase 3 |
| Recruiting | Vitaccess Real MG Registry NCT06064461 | Vitaccess Ltd | — |
| Recruiting | Biomarkers in Autoimmune Disease of Nervous System NCT06502015 | Tongji Hospital | — |
| Recruiting | Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis NCT06371040 | Ting Chang, MD | Phase 1 |
| Recruiting | FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases NCT06539169 | xCures | — |
| Recruiting | Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis NCT06106672 | COUR Pharmaceutical Development Company, Inc. | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis NCT06414954 | NMD Pharma A/S | Phase 2 |
| Recruiting | Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis NCT06441825 | Heinrich-Heine University, Duesseldorf | — |
| Active Not Recruiting | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor NCT06298552 | argenx | Phase 3 |
| Recruiting | Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology NCT07136844 | Centre Hospitalier Universitaire de Liege | N/A |
| Completed | Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomati NCT06381284 | ZS Associates | — |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relap NCT06220201 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 |
| Recruiting | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy NCT06249438 | RenJi Hospital | Phase 1 |
| Completed | Ventilator Weaning Practices in Patients Intubated for Guillain-Barré Syndrome or Myasthenia Gravis NCT07022028 | Poitiers University Hospital | — |
| Unknown | Physical Activity Monitoring in Myasthenia Gravis NCT06277830 | Massachusetts General Hospital | — |
| Recruiting | Myasthenia Gravis Registry in China NCT06241521 | Huashan Hospital | — |
| Not Yet Recruiting | Perioperative Efgartigimod for Thymoma and Myasthenia Gravis NCT06221501 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China NCT04535843 | Huashan Hospital | — |
| Recruiting | The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis NCT05564936 | Ad scientiam | N/A |
| Completed | Psychological Health and Adverse Childhood Experiences in Myasthenia Gravis: Online Mental Health BMI Learning NCT07291713 | Jiann-Horng Yeh | N/A |
| Recruiting | A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgart NCT06299748 | argenx | — |
| Terminated | Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis NCT04226170 | DAS-MG, Inc | Phase 2 |
| Completed | Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis NCT05979688 | University of Alabama at Birmingham | N/A |
| Completed | The Risk of Falls Index for Patients With Neuromuscular Disorders NCT05890833 | LMU Klinikum | — |
| Recruiting | Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis NCT07146425 | Huashan Hospital | — |
| Unknown | MuSK Myasthenia 1000 Study NCT06259071 | Myasthenia Gravis Rare Disease Network | — |
| Recruiting | A Prospective Cohort Study of Myasthenia Gravis in China NCT06006832 | Peking Union Medical College Hospital | — |
| Completed | A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinet NCT07154095 | West China Second University Hospital | Phase 1 |
| Completed | Exploring Accessible Beauty for Individuals With Upper Extremity Deficits NCT05945784 | Casa Colina Hospital and Centers for Healthcare | — |
| Completed | Digital Phenotyping and Lifestyle Intervention in Patients with Myasthenia Gravis NCT05992025 | Uppsala University | N/A |
| Unknown | Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia Gravis NCT05888558 | First Affiliated Hospital of Jinan University | — |
| Completed | Medlink for Diagnosing of Diabetes Mellitus, COPD, CHF, Myasthenia Gravis and Hypertension NCT06256172 | Olawuyi Racett Nigeria Ltd | N/A |
| Completed | Cognitive Functioning in People With Myasthenia Graivs: Impact on Daily Life Activities, Work, Disability and NCT06718855 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | — |
| Recruiting | Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis NCT05828225 | Zhejiang University | Phase 1 |
| Recruiting | Application of Artificial Intelligence in Precision Medicine and Healthcare NCT06879210 | Yi Ting Yeh | N/A |
| Unknown | Pyridostigmine and Amifampridine for Myasthenia Gravis NCT05919407 | Leiden University Medical Center | Phase 3 |
| Completed | Descriptive Analysis of Real-world Data Collected with ME&MGopen NCT05566964 | Ad scientiam | — |
| Recruiting | TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls NCT06754020 | Yi Ting Yeh | N/A |
| Completed | Investigation of the Effects of Proprioceptive Neuromuscular Facilitation Exercises in Patients With Myastheni NCT06158815 | Hacettepe University | N/A |
| Unknown | A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Anterior Mediastinal Disease NCT05455840 | Chang Gung Memorial Hospital | N/A |
| Recruiting | A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis NCT05265273 | Janssen Research & Development, LLC | Phase 2 / Phase 3 |
| Active Not Recruiting | SP Thoracic IDE Study NCT05150210 | Intuitive Surgical | N/A |
| Unknown | Interleukin and Autoantibodies in Myasthenia Gravis. NCT05301153 | Assiut University | — |
| Unknown | Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis NCT05332210 | Harbour BioMed (Guangzhou) Co. Ltd. | Phase 3 |
| Recruiting | The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia Gravis NCT06881173 | Cheng, yu-ting | N/A |
| Recruiting | Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis NCT05337891 | Jagiellonian University | — |
| Completed | Acupuncture in Myasthenia Gravis (AcuMG) NCT05230082 | HealthPartners Institute | N/A |
| Completed | Biomarkers for Fatigue in Patients with Myasthenia Gravis NCT06860347 | Leiden University Medical Center | — |
| Terminated | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis NCT05218096 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Completed | Diaphragm Thickness by Ultrasonography in Neurological Disorders NCT05324176 | Mansoura University | N/A |
| Recruiting | Predictors and Prognostic Factors of Myasthenia Gravis Outcome NCT05214612 | Assiut University | — |
| Completed | Predictors of Myasthenia Gravis Outcome Following Thoracoscopic Thymectomy: Comparative Study Between Thymomat NCT07319689 | Tanta University | — |
| Terminated | Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Grav NCT05132569 | Sanofi | Phase 3 |
| Completed | Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes NCT05408702 | Institut de Myologie, France | — |
| Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266 | Sanguine Biosciences | — |
| Unknown | Immune Profiles in Myasthenia Gravis NCT05095103 | University of Manchester | — |
| Completed | Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patie NCT05039190 | Harbour BioMed (Guangzhou) Co. Ltd. | Phase 3 |
| Completed | Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assiste NCT05694234 | Yonsei University | — |
| Completed | The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis NCT05917184 | Yale University | — |
| Recruiting | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis NCT04951622 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis NCT04678115 | Massachusetts Eye and Ear Infirmary | N/A |
| Active Not Recruiting | Exploring Outcomes and Characteristics of Myasthenia Gravis 2 NCT06002945 | Yale University | — |
| Unknown | Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis NCT04768465 | Da, Yuwei, M.D. | — |
| Withdrawn | Medication Adherence and Non-adherence in Adults With Rare Disease NCT04541875 | Xperiome | — |
| Unknown | A Prospective Cohort Study Of Myasthenia Gravis NCT04674605 | First Affiliated Hospital of Chongqing Medical University | — |
| Recruiting | National, Multicentric Registry Study on Neuroimmunological Diseases in China NCT06443333 | Xuanwu Hospital, Beijing | — |
| Completed | Artificial Intelligence for the Analysis of Video Data of Facial Movement, with a Focus on Myasthenia Gravis NCT06860360 | Leiden University Medical Center | — |
| Active Not Recruiting | Myasthenia Gravis Inebilizumab Trial NCT04524273 | Amgen | Phase 3 |
| Completed | Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares NCT04590716 | doc.ai inc | — |
| Recruiting | Study of Myasthenic Crisis in China NCT04837625 | Huashan Hospital | — |
| Recruiting | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the N NCT04561557 | Tongji Hospital | EARLY_Phase 1 |
| Completed | Subcutaneous Immunoglobulin for Myasthenia Gravis NCT04728425 | University Health Network, Toronto | Phase 2 |
| Completed | A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients NCT04346888 | Harbour BioMed (Guangzhou) Co. Ltd. | Phase 2 |
| Completed | Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis NCT05045248 | American University of Beirut Medical Center | Phase 2 |
| Completed | Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection NCT04695379 | University Hospital, Bordeaux | — |
| Unknown | Influence of Minimally Invasive Thymectomy on the Subsequent Clinical Course of Myasthenia Gravis NCT04158661 | Charite University, Berlin, Germany | — |
| Withdrawn | A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis NCT04224506 | ProgenaBiome | — |
| Completed | A Study of TAK-079 in People With Generalized Myasthenia Gravis NCT04159805 | Takeda | Phase 2 |
| Completed | The Impact of Myasthenia Gravis in the Real World NCT04176211 | Vitaccess Ltd | — |
| Withdrawn | Can Interval Walking Influence on Fatigue in the Danish Cohort of Myasthenia Gravis Patients NCT03900585 | Rigshospitalet, Denmark | N/A |
| Completed | Physical Activity and Fatigue in Myasthenia Gravis NCT03905473 | Rigshospitalet, Denmark | — |
| Completed | A Study of RVT-1401 in Myasthenia Gravis (MG) Patients NCT03863080 | Immunovant Sciences GmbH | Phase 2 |
| Completed | Burden of Disease in Myasthenia Gravis NCT03979521 | Charite University, Berlin, Germany | — |
| Unknown | Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis NCT03914638 | University of Aarhus | Phase 2 / Phase 3 |
| Completed | Rhythmic Auditory Stimulation and Walking Speed in the 6-minute Walk Test NCT03905161 | Rigshospitalet, Denmark | — |
| Completed | Clinical Trial to Improve the Magnetic Levator Prosthesis NCT03818204 | Massachusetts Eye and Ear Infirmary | N/A |
| Completed | Neurology Inpatient Clinical Education Trial NCT03826056 | Dartmouth-Hitchcock Medical Center | N/A |
| Completed | A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Grav NCT03759366 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Completed | The Effect of Spinal Stabilization Exercises in Patients With Myasthenia Gravis NCT03743740 | Hacettepe University | N/A |
| Unknown | The Curative Effect of Extended Thymectomy Performed Through Subxiphoid-right VATS Approach With Elevation of NCT03613272 | Jiang Fan | N/A |
| Unknown | Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis NCT03510546 | University of Aarhus | Phase 4 |
| Completed | Interval Inspiratory Training and Aerobic Exercise for Muscle Recovery in Myasthenia Gravis Post-Hospitalizati NCT06624345 | Chang Gung University | N/A |
| Completed | Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia NCT03052751 | UCB Biopharma S.P.R.L. | Phase 2 |
| Completed | Myasthenia Gravis and Psyche NCT03205306 | Charite University, Berlin, Germany | — |
| Terminated | Trial of Orencia in Patients With Myasthenia Gravis NCT03059888 | Johns Hopkins University | EARLY_Phase 1 |
| Recruiting | Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA) NCT06940323 | University of California, San Francisco | — |
| Unknown | Clinical Prognosis and Progression of Myasthenia Gravis Patients NCT04101578 | Da, Yuwei, M.D. | — |
| Unknown | Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia Gravis NCT03597373 | First Affiliated Hospital, Sun Yat-Sen University | — |
| Completed | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis NCT02965573 | argenx | Phase 2 |
| Completed | Biomarkers in Neural Disorders NCT02761707 | University of Pennsylvania | — |
| Recruiting | The EXPLORE MG Registry for Myasthenia Gravis NCT03792659 | Yale University | — |
| Completed | Pilot Study: Use of the Saccadometer to Detect Characteristic Saccadic Peak Velocity in Myasthenia Gravis Pati NCT06501794 | University of Liverpool | N/A |
| Completed | Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis NCT02609022 | CuraVac | Phase 1 / Phase 2 |
| Completed | Univent Tube for Thoracoscopic Thymectomy in Myasthenic Patients NCT06101407 | Nguyen Dang Thu | — |
| Completed | Tissue Repository for Studies of Myasthenia Gravis NCT02902536 | Johns Hopkins University | — |
| Completed | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis NCT02473965 | Grifols Therapeutics LLC | Phase 2 |
| Completed | Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis NCT02100969 | Mazen Dimachkie, MD | Phase 2 |
| Terminated | Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) NCT02102594 | Charite University, Berlin, Germany | Phase 2 |
| Completed | Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis NCT02066519 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) NCT02774239 | University of Alberta | Phase 3 |
| Unknown | The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor NCT02317224 | Tang-Du Hospital | Phase 2 |
| Completed | Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F NCT02470364 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis NCT02110706 | Yale University | Phase 2 |
| Recruiting | Myasthenia Gravis Foundation of America Global MG Patient Registry NCT06617741 | Myasthenia Gravis Foundation of America | — |
| Completed | Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders NCT02118805 | Beth Israel Deaconess Medical Center | — |
| Completed | Therapeutic Plasma Exchange in MG NCT01927692 | Duke University | — |
| Completed | The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thym NCT01727193 | First Affiliated Hospital, Sun Yat-Sen University | Phase 3 |
| Unknown | A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis NCT01555580 | Muscular Dystrophy Association | EARLY_Phase 1 |
| Unknown | Perception and Multisensory Integration in Neurological Patients Using fMRI NCT01469858 | Hadassah Medical Organization | N/A |
| Terminated | Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis NCT01828294 | St. Louis University | Phase 1 |
| Completed | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis NCT01325571 | Astellas Pharma Inc | Phase 3 |
| Terminated | Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis NCT01268280 | Cytokinetics | Phase 2 |
| Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168 | Sanford Health | — |
| Unknown | Study of an Intervention to Improve Problem List Accuracy and Use NCT01105923 | Brigham and Women's Hospital | N/A |
| Unknown | Exercise for Stable Myasthenia Gravis NCT01047761 | Baltimore VA Medical Center | Phase 1 |
| Completed | Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis NCT00987116 | Assistance Publique - Hôpitaux de Paris | Phase 4 |
| Unknown | Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis NCT00997412 | Qualitix Clinical Research Co., Ltd. | N/A |
| Completed | Efficacy of Methotrexate in Myasthenia Gravis NCT00814138 | University of Kansas Medical Center | Phase 2 |
| Terminated | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis NCT00727194 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Active Not Recruiting | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases NCT00716066 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis NCT00774462 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | The Role of the Thymus in Myasthenia Gravis NCT01102192 | Charite University, Berlin, Germany | — |
| Completed | Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy NCT00294658 | University of Alabama at Birmingham | Phase 3 |
| Completed | FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients NCT00309088 | Astellas Pharma Inc | Phase 3 |
| Completed | An Open Study for Steroid Resistant, Non-Thymectomized MG Patients NCT00309101 | Astellas Pharma Inc | Phase 3 |
| Completed | Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis NCT00306033 | University Health Network, Toronto | Phase 3 |
| Completed | Mycophenolate Mofetil in Myasthenia Gravis NCT00285350 | FDA Office of Orphan Products Development | Phase 3 |
| Terminated | Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis NCT00424489 | Northwestern University | Phase 1 |
| Enrolling By Invitation | Serum Auto-Antibodies in Neurological Diseases NCT00704626 | University of California, Davis | — |
| Terminated | Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis NCT00004682 | University of Texas | N/A |
| Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity NCT03941184 | Mayo Clinic | — |